Providers

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.

Closer monitoring of youth hypertension could lessen the disease in adults, reducing overall costs and morbidity related to cardiovascular disease (CVD), new research shows.

Amy Shapiro, MD, medical director of Indiana Hemophilia and Thrombosis Center, joined AJMC to shed light on a broadly overlooked disorder: plasminogen deficiency type-1.

Immune checkpoint blockade therapy works by preventing the binding of checkpoint and partner proteins, thereby allowing T cells to continue their work of attacking and killing cancer cells.

A follow-up study utilizing interviews and survey responses demonstrates that patients prefer rhenium-188 skin cancer therapy (RSCT) over surgery in the treatment of their non-melanoma skin cancer.

While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.

The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.

Risk assessments of drug-related problems for cardiac surgery patients can be conducted by implementing a framework for patient safety.

Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.

Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.

The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.

Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.

A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.

Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas.

New therapies being developed are moving into earlier lines of therapy, with the idea that most patients with early-stage prostate cancer will progress and need additional therapy later.

Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.

Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.

The findings show exercise-induced hypertension increases myocardial oxygen demand.

New therapies are helping patients, but are also driving up overall costs of care.

A prospective study found evidence of serum neurofilament light (sNfL) level increases in patients affected by active forms of relapsing-remitting multiple sclerosis (RRMS); however, these findings were not significant enough to suggest sNfL measurements replace clinical or MRI monitoring of disease activity.

Michael Morse, MD, FACP, MHS, medical oncologist at Duke Cancer Center, explained gaps in care access and equity that must be addressed to ensure all patients with liver cancer can get the treatments they need.

In this interview, Chris Pagnani, MD, PC, emphasizes the benefits of telemedicine and its role in improving accessibility, particularly in the realm of mental health care.

Risk factors and prostate-specific antigen are both important when determining how to move forward with treatment, explained Angela Jia, MD, PhD, of University Hospitals and Case Western Reserve University School of Medicine.

There are increasingly more bladder-sparing strategies for patients with even aggressive bladder cancer, said Alexander Kutikov, MD, FACS, chair, Department of Urology, Fox Chase Cancer Center.

Physicians treated the patient without surgery, although they said the patient’s case is particularly challenging and treatment was ongoing at the time of the report’s writing.

During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.

With more therapies available in bladder, kidney, and prostate cancers, collaboration among health care providers can help ensure patients are getting the most appropriate care for their type and stage of cancer, said Mary Dunn, MSN, NP-C, OCN, RN, of University of North Carolina.

Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.

In 2024, the Asembia Specialty Pharmacy Summit celebrated 20 years and speakers highlighted the conversations around improving access and affordability taking place at the meeting.

Survey results from more than 1500 patients with diabetes revealed that 57% believed glucagon-like peptide-1 (GLP-1) weight loss drugs alone could be a "silver bullet" for managing their health goals.